---
title: Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles
nct_id: NCT02159261
overall_status: COMPLETED
sponsor: Bayer
study_type: OBSERVATIONAL
primary_condition: Contraception
countries: Russia
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02159261.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02159261"
ct_last_update_post_date: 2017-08-09
last_seen_at: "2026-05-12T07:03:15.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles

**Official Title:** A Prospective Multicenter Non-interventional Study on Patients and Physicians Satisfaction of Yaz Plus

**NCT ID:** [NCT02159261](https://clinicaltrials.gov/study/NCT02159261)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 1500
- **Lead Sponsor:** Bayer
- **Conditions:** Contraception
- **Start Date:** 2014-07-15
- **Completion Date:** 2016-08-14
- **CT.gov Last Update:** 2017-08-09

## Brief Summary

Local prospective multicenter non-comparative non-interventional observational study. It's planed to assess satisfaction of patients and physicians with results of Yaz Plus treatment for 13 cycles in real practice.

## Detailed Description

Non-interventional, Yaz Plus, Contraception, Assess satisfaction, Russian Federation.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Female patients ≥ 18 years old
* Requiring contraception
* Prescribed with Yaz Plus for the first time

Exclusion Criteria:

* Contraindications for the use of Yaz Plus in accordance with the local product information
```

## Arms

- **Cohort 1** — Female patients ≥ 18 years old requiring contraception.

## Interventions

- **BAY98-7071_EE20/DRSP/L-5-MTHF** (DRUG) — Patients treated by Physicians under approved local prescriptions

## Primary Outcomes

- **Satisfaction measured with a Likert response scale (from 1 - poor to 5 - excellent)** _(time frame: Up to 12 months)_

## Secondary Outcomes

- **Changes in EVAPIL scale for assessment of tolerability of oral contraceptives.** _(time frame: Baseline to 12 months)_
- **Number of participants with adverse events as a measure of safety and tolerability** _(time frame: Up to 12 months)_

## Locations (1)

- Many Locations, Russia

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.|many locations||russia` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02159261.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02159261*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*